Treatment with dapagliflozin and empagliflozin reduces concentrations of N4-acetylcytidine in plasma, a biomarker associated with vascular damage.
Diabetes drugs reduce a newly-discovered marker of blood vessel damage, revealing a new biological mechanism explaining their heart-protective benefits.
This RCT demonstrates that SGLT2 inhibitors (dapagliflozin and empagliflozin) significantly reduce plasma N4-acetylcytidine, a recently identified biomarker of vascular endothelial damage, in diabetic patients with established atherosclerosis. This finding provides a novel mechanistic pathway linking SGLT2 inhibition to vascular protection, complementing existing evidence on cardiorenal mechanisms.
What the study was
- Study design
- Randomized controlled trial
- Population
- Patients with type 2 diabetes and established atherosclerosis
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Cardiovascular diabetology
Why it surfaced
RCT demonstrating SGLT2 inhibitors reduce N4-acetylcytidine (novel vascular damage biomarker) in diabetic atherosclerosis. Provides new mechanistic insight into SGLT2 vascular protection. Published in Cardiovasc Diabetol (Schmieder RE, Maas R — Erlangen-Nuremberg group).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.